In an exciting development that highlights the rapidly evolving field of medicinal cannabis, a global healthcare and supply company is set to create 100 new jobs with an ambitious expansion in Scotland. But here's where it gets controversial: this move underscores a significant shift in the industry—raising questions about local production versus dependence on imports, and the broader societal implications. Let’s dive into what this means for the region and the industry as a whole.
A multi-national firm specializing in medical supplies, Breathe Life Sciences (BLS), announced plans to establish a state-of-the-art cannabis manufacturing facility in the Scottish Borders. The initial phase will generate around 36 jobs by the end of next year, with a target to grow the workforce to approximately 100 employees over the next three years. This strategic expansion makes BLS one of the few companies to develop local manufacturing infrastructure for medicinal cannabis within the UK.
Based out of Sydney, Australia, BLS already operates licensed production sites in Manchester, Prague, and Nagoya, Japan. Their CEO, Sam Watson, explained that Scotland’s entry into this burgeoning industry is driven by an increasing global demand, which the company aims to meet through local manufacturing.
Since the legalisation of medicinal cannabis in the UK in 2018, the market has experienced substantial growth, now valued at roughly £250 million annually. Industry reports suggest that the number of patients benefitting from medicinal cannabis could more than double from the current 80,000 to over 190,000 by the decade’s end. This rapid increase in demand and the UK's strategic position within Europe were key factors convincing BLS to invest in Scotland.
Importantly, local directors Gavin and Andrew Ogilvie from Melrose played a pivotal role in this decision, citing the region’s potential as a hub for pharmaceutical manufacturing and innovation. Mr. Watson emphasized that the UK is the fastest-growing market for medicinal cannabis in Europe. He also pointed out that while most products are imported, there are very few UK-based manufacturers, creating a significant opportunity to develop a domestic pharmaceutical industry.
Public sentiment has largely supported the legalization of medicinal cannabis, especially considering its rigorous testing, safety standards, and affordability compared to previous options. Patients currently access cannabis-based treatments through the NHS or via private providers to help manage conditions like epilepsy, multiple sclerosis, or chemotherapy side effects. Ongoing clinical trials are also assessing its potential for providing relief from chronic pain.
BLS’s Scottish plant aims to serve both local and international markets by manufacturing and distributing patient-specific products. The project has received nearly £350,000 in grants and a further £500,000 loan from South of Scotland Enterprise (SOSE), reflecting regional support for developing the life sciences sector.
According to SOSE Chairman Russel Griggs, the south of Scotland is rapidly establishing itself as a key player in the emerging medicinal cannabis industry. He highlighted that BLS’s investment will not only bring economic growth but will also create highly skilled jobs—ranging from entry-level roles to specialized pharmaceutical positions. The company’s decision to set up in the Borders was also personally meaningful to director Gavin Ogilvie, who grew up in the area.
Despite these promising developments, it’s important to note that the facility will not cultivate cannabis on-site. Instead, it will operate under a license from the Home Office—meaning that rigorous regulatory approval is still pending before full-scale production can begin. Although much of the facility has been fitted out and key senior staff have been hired, the project will undergo thorough scrutiny before receiving final approval.
Looking ahead, BLS aims to commence wider recruitment efforts after summer, with production expected to start before year’s end. The company emphasizes that the plant’s establishment will contribute positively to the local economy, providing opportunities for a skilled workforce and supporting regional innovation.
Gavin Ogilvie expressed his pride in the initiative, stating, 'This is my hometown, and developing a pharmaceutical manufacturing base in the Borders was a top priority for us. We’re grateful for the support from SOSE and Scottish Borders Council to turn this vision into reality.'
So, as Scotland prepares to become a key player in the medicinal cannabis industry, we must consider both the opportunities and the challenges that come with it. Does local manufacturing truly benefit society by creating jobs and reducing reliance on imports? And how should we balance commercial growth with regulatory oversight and public concerns? These are questions worth pondering—and debating—throughout this exciting transformation.
